Matrix metalloproteinases and tissue inhibitors of metalloproteinases in chronic kidney disease and acute kidney injury: a systematic review of the literature

被引:3
|
作者
Sampieri, C. L. [1 ]
Orozco-Ortega, R. A. [2 ]
机构
[1] Univ Veracruzana, Inst Salud Publ, Av Luis Castelazo Ayala S-N, Xalapa 91190, Veracruz, Mexico
[2] Univ Veracruzana, Fac Bioanal, Xalapa, Veracruz, Mexico
关键词
Matrix metalloproteinases; tissue inhibitors of metalloproteinases; chronic kidney disease; acute kidney injury; URINARY BIOMARKERS; MATRIX-METALLOPROTEINASE-9; SERUM; STORAGE; DYSREGULATION; DEGRADATION; ZYMOGRAPHY; MORTALITY; MARKER; BLOOD;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: Matrix metalloproteinases (MMPs) are a family of zinc-dependent proteinases involved in remodeling the extracellular matrix. Tissue inhibitors of metalloproteinases (TIMPs) are a family of four proteins that act to limit the degradative actions of MMPs. Chronic kidney disease (CKD) and acute kidney injury (AKI) are public health problems worldwide, the prevalence of which has been increasing. Recent concept considers MMPs and TIMPs as critical factors before the onset of microalbuminuria, as well as accelerating factors associated with the breakdown of the glomerular basement membrane, renal scarring, and fibrosis during the progression of kidney diseases. Here we reviewed studies of the expression of MMPs and TIMPs in humans, using as clinical samples serum, plasma, and urine, with a focus on their potential role as molecular markers in CKD and AKI, as non-invasive markers. Material and methods: We used as data sources, studies at Medline database using combinations of the following keywords: CKD, AKI, MMP, TIMP, serum, plasma, and urine. Results: Evidence suggests that MMPs/TIMPs could be potential targets for therapeutic intervention in kidney diseases; future studies should attempt to improve the diagnostic or prognostic power of these families. Discussion: Considering published guides, such as biospecimen reporting for improved study quality (BRISQ), strengthening the reporting of observational studies in epidemiology (STROBE), an updated list of essential items for reporting diagnostic accuracy studies (STARD), transparent reporting of a multivariate prediction model for individual prognosis or diagnosis (TRIPOD), and on the studies reviewed here, we have adapted published recommendations and proposed other news in order to enhance the transparency and quality of MMPs/TIMPs research in CKD and AKI. This review reinforces the complexities of MMPs/TIMPs in the pathobiology of the kidney and the need for well-designed and transparent biomedical studies.
引用
收藏
页码:99 / 104
页数:6
相关论文
共 50 条
  • [31] Localization of matrix metalloproteinases and their inhibitors in experimental progressive kidney scarring
    Ahmed, A. K.
    Haylor, J. L.
    El Nahas, A. M.
    Johnson, T. S.
    KIDNEY INTERNATIONAL, 2007, 71 (08) : 755 - 763
  • [32] Urine matrix metalloproteinases and their extracellular inducer EMMPRIN in children with chronic kidney disease
    Musial, Kinga
    Bargenda, Agnieszka
    Zwolinska, Danuta
    RENAL FAILURE, 2015, 37 (06) : 980 - 984
  • [33] Activation of Arterial Matrix Metalloproteinases Leads to Vascular Calcification in Chronic Kidney Disease
    Chen, Neal X.
    O'Neill, Kalisha D.
    Chen, Xianming
    Kiattisunthorn, Kraiwiporn
    Gattone, Vincent H.
    Moe, Sharon M.
    AMERICAN JOURNAL OF NEPHROLOGY, 2011, 34 (03) : 211 - 219
  • [34] MATRIX METALLOPROTEINASES AND THEIR EXTRACELLULAR INDUCER (EMMPRIN) IN THE URINE OF CHILDREN WITH CHRONIC KIDNEY DISEASE
    Musial, Kinga
    Zwolinska, Danuta
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2013, 28 : 517 - 517
  • [35] Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human chondrosarcomas
    Söderström, M
    Aro, HT
    Ahonen, M
    Johansson, N
    Aho, A
    Ekfors, T
    Böhling, T
    Kähäri, VM
    Vuorio, E
    APMIS, 2001, 109 (04) : 305 - 315
  • [36] Circulating Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Cardiac Amyloidosis
    Tanaka, Komei
    Essick, Eric E.
    Connors, Lawreen H.
    Seldin, David C.
    Sam, Flora
    CIRCULATION, 2011, 124 (21)
  • [37] Matrix metalloproteinases, tissue inhibitors of metalloproteinases, and heart failure outcomes
    Bhalla, Vikas
    Georgiopoulou, Vasiliki V.
    Azeem, Ali A.
    Marti, Catherine N.
    Cole, Robert T.
    Laskar, Sonjoy R.
    De Staercke, Christine
    Hooper, W. Craig
    Smith, Andrew L.
    Kalogeropoulos, Andreas P.
    Butler, Javed
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2011, 151 (02) : 237 - 239
  • [38] Occurrence of matrix metalloproteinases and tissue inhibitors of metalloproteinases in tuberculous pleuritis
    Hoheisel, G
    Sack, U
    Hui, DSC
    Huse, K
    Chan, KS
    Chan, KK
    Hartwig, K
    Schuster, E
    Scholz, GH
    Schauer, J
    TUBERCULOSIS, 2001, 81 (03) : 203 - 209
  • [39] Circulating Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Cardiac Amyloidosis
    Tanaka, Komei
    Essick, Eric E.
    Doros, Gheorghe
    Tanriverdi, Kahraman
    Connors, Lawreen H.
    Seldin, David C.
    Sam, Flora
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2013, 2 (02): : e005868
  • [40] Matrix metalloproteinases and tissue inhibitors of metalloproteinases - Structure, function, and biochemistry
    Visse, R
    Nagase, H
    CIRCULATION RESEARCH, 2003, 92 (08) : 827 - 839